Home | Publications | IT & eHealth place holder
place holder place holder

IT & eHealth

Leading Drug Delivery Companies and Technologies: Competitive landscape, company profiles and technological developments


Publication Date   June 2008
Publisher   Datamonitor
Product Type   Report
Pages   175
ISBN Number   not applicable
Product Code   DAT01481
Ask a question about this product?

Price £2,025.00

approximately: $2,959 | €2,219

Summary


Leading Drug Delivery Companies and Technologies
Competitive landscape, company profiles and technological developments

Business Intelligence for the Pharmaceutical Industry


Business Insights' portfolio of healthcare management reports is designed to help you make well informed and timely business decisions. We understand the problems facing today's pharmaceutical and healthcare executives when trying to drive your business forward, and appreciate the importance of accurate, up-to-date, incisive product, market and company analysis. We help you to crystallize your business decisions.
The strength of our research and analysis is derived from access to unparalleled databases and libraries of information and the use of proprietary analytic techniques. Business Insights reports are authored by independent experts and contain findings garnered from dedicated primary research. Our authors' leading positions secure them access to interview key executives and to establish which issues will be of greatest strategic significance for the industry
Our healthcare portfolio of reports can be used across a wide range of business functions to assess market conditions and devise future strategy. Our reports cover key areas including strategy, industry analysis, market outlook, new business opportunities and strategic insight.

Some key findings from this report

The oral delivery system continues to dominate the drug delivery market due to convenient usage, cost-effectiveness and low frequency of administration. Needleless injectables, PEGylation technologies and micro-electromechanical devices are among the novel technologies with the greatest growth potential The market for parenteral drugs and solutions sold in prefilled syringes and premixed IV systems will grow, due to the ease of administration and resistance to infections associated with these methods. The needle-free delivery sector will rise to $3bn by 2010 Pulmonary delivery technologies are increasingly prevalent in pain management, cystic fibrosis and diabetes. Pulmonary-based delivery vehicles are currently the focus of a number of major companies including Nektar, Aradigm, 3M, and Alkermes Dry powder inhalers will secure the largest share of sales within the asthma market, as demand for treatments in this therapy area continues to expand. However, MDI products will experience a relatively higher rate of growth due to consistent improvements in particle size and safe propellant delivery

Leading Drug Delivery Companies and Technologies

Over the last decade, the drug delivery industry has evolved to become a key area in the development of value-added pharmaceutical products. The global market grew from $15bn to $40bn during 2000-2006 as companies increasingly turned to drug delivery technologies as a means of expanding product lifecycles, enhancing drug efficacy and maximizing revenues. Although the market is still dominated by the oral drug delivery system, a number of novel technologies are emerging across all systems of delivery. However, the pure drug delivery company model is rapidly becoming extinct as leading players attempt to consolidate their strategic opportunities by expanding their focus towards manufacturing, a trend that is expected to accelerate over the next five years.

'Leading Drug Delivery Companies and Technologies' is a new report published by Business Insights that examines the current and future trends that are shaping the drug delivery market and reviews the key emerging technologies across major systems of drug delivery. This report identifies the product portfolios and targeted therapeutic areas of leading drug delivery companies in addition to assessing their technology platforms to provide guidance over their applicability, regulatory implications and developmental progress. This report also evaluates the opportunities and threats facing each of the companies profiled and provides a comparative analysis of the growth strategies used to facilitate successful deals and collaborations.

Identify key trends and developments in the global drug delivery market, assess the performances and portfolios of leading drug delivery companies and benchmark their strategies with this new report.

Top reasons to order your copy today

Discover the key issues and trends in the global drug delivery market with this report's analysis of market size and growth, the commercial value of drug delivery systems and the extended strategic focus of growing numbers of drug delivery companies Identify the dynamics of major drug delivery systems by evaluating the latest market developments and technological innovations in oral, pulmonary, injectable and transdermal delivery platforms Assess the leading players in the drug delivery market with this report's review of the opportunities and threats, financial performances and R&D expenditures of Biovail, Elan, SkyePharma, Alkermes, Bioject, QLT, Nektar, Aradigm, Antares, Noven, Alza and 3M Benchmark the strategies of leading drug delivery companies by evaluating their product portfolios and pipelines, deals and alliances, targeted therapeutic areas and technology platforms

Key issues examined in this report

Technology driving growth. Drug delivery technologies are being used to boost revenues and enhance product efficacy by developing future commercial opportunities and expanding product lifecycles Expanding strategic focus. A growing number of drug delivery companies are evolving into specialty pharma companies. Widening the core business to incorporate manufacturing is a strategy increasingly used to enhance revenues Stagnant R&D investment. The companies featured in this report recorded an average growth in R&D expenditure of just 6% during 2003-2007. This low growth in R&D spend is likely to inhibit the discovery and development of new products in the short term Inhaled insulin setback. The development of inhaled insulin has been the focus of many companies operating in the pulmonary drug delivery field. However, a high number late-stage terminations have raised doubts over the commercial potential of this delivery vehicle

Your questions answered

What are the major issues surrounding drug delivery within the global pharma industry? What are the latest innovations and developments in different drug delivery vehicles? What are the market dynamics for oral, injectable, pulmonary and transdermal drug delivery systems? What are the key technologies and growth strategies of leading drug delivery companies? What are the product portfolios, pipeline candidates, financial performances and R&D expenditures of these leading companies? What opportunities and threats will drug delivery companies face in the future?

Content


  • Table of Contents
    • Leading Drug Delivery Companies and Technologies
    • Executive Summary
    • Overview on drug delivery industry
    • Oral drug delivery system
    • Injectable drug delivery system
    • Pulmonary drug delivery system
    • Transdermal drug delivery system
  • Chapter 1 Overview of drug delivery
    • industry
    • Summary
    • What is this report about?
    • Methodology
    • Drug delivery overview
    • Role of drug delivery in the pharma landscape
    • Revenue boosters for pharma companies
    • Patent extension and protection from generic competition
    • Reformulation of existing products
    • Optimizing returns on R&D investment
    • Compliance, bioavailability and safety benefits
    • From drug delivery to specialty pharma
    • Markets for drug delivery systems
    • Oral drug delivery system
    • Pulmonary
    • Injectable
    • Transdermal
    • Market dynamics
  • Chapter 2 Oral drug delivery system
    • Summary
    • Synopsis
    • Oral drug delivery technologies
    • Technologies for fast-dissolving and taste-masking pills
    • Controlled oral drug delivery
    • Types of controlled release
    • Dynamics of oral drug delivery market
    • Biovail
    • Key technologies
    • Therapeutic focus
    • Product portfolio and pipeline candidates
    • Recent financial performance
    • Growth strategies
    • Expanding its presence in diverse geographical areas
    • Deriving growth from strategic alliances
    • Deals and alliances
    • SWOT analysis
    • Strengths
    • Weaknesses
    • Opportunities
    • Threats
    • Elan
    • Key technologies
    • NanoCrystal technology
    • OCR technology
    • Therapeutic focus
    • Product portfolio and pipeline candidates
    • Recent financial performance
    • Growth strategies
    • Alzheimer's disease
    • Pipeline products
    • Deals and alliances
    • SWOT analysis
    • Strengths
    • Weaknesses
    • Opportunities
    • Threats
    • SkyePharma
    • Key technologies
    • Oral drug delivery technologies
    • Inhalation technologies
    • Insoluble drug delivery (IDD) technology
    • Therapeutic focus
    • Products portfolio and pipeline candidates
    • Recent financial performance
    • Growth strategies
    • Focus on building pipeline of products
    • Deals and alliances
    • SWOT analysis
    • Strengths
    • Weaknesses
    • Opportunities
    • Threats
  • Chapter 3 Injectable drug delivery system
    • Summary
    • Synopsis
    • Injectable drug delivery technologies
    • Needleless injection device technology
    • Sustained/controlled release technology
    • PEGylation
    • Therapeutic focus
    • Dynamics of the injectable drug delivery market
    • Alkermes
    • Introduction
    • Key technologies
    • Medisorb injectable technology
    • AIR pulmonary drug delivery technology
    • Therapeutic focus
    • Product portfolio and pipeline candidates
    • Recent financial performance
    • Growth strategies
    • Deals and alliances
    • SWOT analysis
    • Strengths
    • Weaknesses
    • Opportunities
    • Threats
    • Bioject
    • Introduction
    • Key technologies
    • Needle-free injection technology
    • Therapeutic Focus
    • Product portfolio and pipeline candidates
    • Recent financial performance
    • Growth strategies
    • Developing clinical research collaborations
    • Deals and alliances
    • SWOT analysis
    • Strengths
    • Weaknesses
    • Opportunities
    • Threats
    • QLT
    • Key technologies
    • Atrigel drug delivery system
    • PDT
    • Therapeutic focus
    • Product portfolio and pipeline candidates
    • Recent company financials
    • Growth strategies
    • Focus on key therapeutic areas
    • Deals and alliances
    • SWOT analysis
    • Strengths
    • Weaknesses
    • Opportunities
    • Threats
  • Chapter 4 Pulmonary drug delivery system
    • Summary
    • Synopsis
    • Inhaled formulations
    • Therapeutic focus
    • Dynamics of the pulmonary drug delivery market
    • Nektar Therapeutics
    • Key technologies
    • Dry powder pulmonary technology
    • Liquid pulmonary technology
    • PEGylation technology
    • Therapeutic focus
    • Product portfolio and pipeline candidates
    • Recent financial performance
    • Growth strategies
    • Shifting focus from drug delivery to become a specialty pharma
    • company
    • Deals and alliances
    • SWOT analysis
    • Strengths
    • Weaknesses
    • Opportunities
    • Threats
    • Aradigm
    • Key technologies
    • AERx pulmonary drug delivery system
    • Liposomal Formulations
    • Therapeutic focus
    • Product portfolio and pipeline candidates
    • Recent financial performance
    • Growth strategies
    • Deals and alliances
    • SWOT analysis
    • Strengths
    • Weaknesses
    • Opportunities
    • Threats
    • 3M
    • Key technologies
    • Pulmonary drug delivery technology
    • Transdermal drug delivery technology
    • Therapeutic focus
    • Product portfolio and pipeline candidates
    • Growth strategies
    • Deals and alliances
  • Chapter 5 Transdermal drug delivery system
    • Summary
    • Synopsis
    • Transdermal drug delivery technologies
    • Passive formulations
    • Active formulations
    • Therapeutic focus
    • Dynamics of the transdermal drug delivery market
    • Antares
    • Key technologies
    • Advanced transdermal delivery
    • Injection devices
    • Easy Tec fast melt oral disintegrating tablets
    • Therapeutic focus
    • Product portfolio and pipeline candidates
    • Recent financial performance
    • Growth strategies
    • Deals and alliances
    • SWOT analysis
    • Strengths
    • Weaknesses
    • Opportunities
    • Threats
    • Noven
    • Key technologies
    • DOT Matrix technology
    • Therapeutic focus
    • Product portfolio and pipeline candidates
    • Recent financial performance
    • Growth strategies
    • Deals and alliances
    • SWOT analysis
    • Strengths
    • Weaknesses
    • Opportunities
    • Threats
    • Alza
    • Key technologies
    • D-Trans
    • E-Trans
    • Macroflux
    • Stealth
    • Alzamer
    • Oros
    • Therapeutic focus
    • Product portfolio and pipeline candidate
    • Deals and alliances
    • SWOT analysis
    • Strengths
    • Weaknesses
    • Opportunities
    • Threats
  • Chapter 6 Conclusion
    • Financials
    • Growth strategies
    • Outlook
    • Glossary
    • Index
  • List of Figures
    • Figure 1.1: Drug delivery technologies are revenue boosters for pharma companies
    • Figure 1.2: Procardia XL patent expiry
    • Figure 1.3: Cardizem's reformulation strategy
    • Figure 1.4: Compliance, bioavailability and safety benefits via effectice drug delivery
    • Figure 1.5: Positioning of key drug delivery companies
    • Figure 1.6: Key drug delivery systems market share, 2006
    • Figure 2.7: Biovail financial performance, $m, 2003-2007
    • Figure 2.8: Biovail SWOT analysis
    • Figure 2.9: Elan financial performance, 2003-2007 ($m)
    • Figure 2.10: Elan SWOT analysis
    • Figure 2.11: SkyePharma financial performance, $m, 2003-2007
    • Figure 2.12: SkyePharma SWOT analysis
    • Figure 3.13: Alkermes financial performance, 2003-2007
    • Figure 3.14: Alkermes SWOT analysis
    • Figure 3.15: Bioject financial performance, 2003-2007 ($m)
    • Figure 3.16: Bioject SWOT analysis
    • Figure 3.17: QLT financial performance, 2003-2007 ($m)
    • Figure 3.18: QLT SWOT analysis
    • Figure 4.19: Nektar financial performance, 2003-2007 ($m)
    • Figure 4.20: Nektar SWOT analysis
    • Figure 4.21: Aradigm financial performance, 2003-2007 ($m)
    • Figure 4.22: Aradigm SWOT analysis
    • Figure 5.23: Antares financial performance, 2003-2007 ($m)
    • Figure 5.24: Antares SWOT analysis
    • Figure 5.25: Noven financial performance, 2003-2007 ($m)
    • Figure 5.26: Noven SWOT analysis
    • Figure 5.27: Alza SWOT analysis
    • Figure 6.28: Comparative analysis of key drug delivery companies (I)
    • Figure 6.29: Comparative analysis of key drug delivery companies (II)
  • List of Tables
    • Table 2.1: Biovail snapshot
    • Table 2.2: Biovail oral marketed products
    • Table 2.3: Biovail oral product sales, 2006-2007 ($m)
    • Table 2.4: Biovail oral product pipeline
    • Table 2.5: Biovail financial performance, 2003-2007 ($m)
    • Table 2.6: Elan snapshot
    • Table 2.7: Elan oral marketed products
    • Table 2.8: Elan NanoCrystal product pipeline
    • Table 2.9: Elan financial performance, 2003-2007 ($m)
    • Table 2.10: SkyePharma snapshot
    • Table 2.11: SkyePharma oral marketed products
    • Table 2.12: Skye Pharma oral product pipeline
    • Table 2.13: SkyePharma financial performance, 2003-2007
    • Table 3.14: Alkermes snapshot
    • Table 3.15: Alkermes injectable marketed products
    • Table 3.16: Alkermes injectable product sales, 2006-2007 ($m)
    • Table 3.17: Alkermes injectable product pipeline
    • Table 3.18: Alkermes financial performance, 2003-2007 ($m)
    • Table 3.19: Bioject snapshot
    • Table 3.20: Bioject injectable marketed products
    • Table 3.21: Bioject injectable product sales, 2006-2007 ($m)
    • Table 3.22: Bioject financial performance, 2003-2007 ($m)
    • Table 3.23: QLT snapshot
    • Table 3.24: QLT injectable marketed products
    • Table 3.25: QLT injectable product sales, 2006-2007 ($m)
    • Table 3.26: QLT injectable product pipeline
    • Table 3.27: QLT financial performance, 2003-2007 ($m)
    • Table 4.28: Nektar snapshot
    • Table 4.29: Nektar pulmonary marketed products
    • Table 4.30: Nektar pulmonary product sales, 2006-2007 ($m)
    • Table 4.31: Nektar pulmonary product pipeline
    • Table 4.32: Nektar financial performance, 2003-2007 ($m)
    • Table 4.33: Aradigm snapshot
    • Table 4.34: Aradigm pulmonary product pipeline
    • Table 4.35: Aradigm financial performance, 2003-2007 ($m)
    • Table 4.36: 3M snapshot
    • Table 4.37: 3M pulmonary marketed products
    • Table 5.38: Antares snapshot
    • Table 5.39: Antares transdermal marketed products
    • Table 5.40: Antares transdermal product pipleine
    • Table 5.41: Antares financial performance, 2003-2007 ($m)
    • Table 5.42: Noven snapshot
    • Table 5.43: Noven transdermal marketed products
    • Table 5.44: Noven transdermal product pipeline
    • Table 5.45: Noven financial performance, 2003-2007 ($m)
    • Table 5.46: Alza snapshot
    • Table 5.47: Alza transdermal marketed products